Recombinant Mouse 2-acylglycerol O-acyltransferase 2 (Mogat2)

What is the enzymatic mechanism of recombinant mouse Mogat2 in lipid metabolism?

Recombinant mouse Mogat2 catalyzes the synthesis of diacylglycerol (DAG) from monoacylglycerol (MAG) and fatty acyl-CoA substrates, a critical step in triglyceride (TAG) biosynthesis. In vitro assays using radiolabeled substrates (e.g., [³H]-oleoyl-LPA) reveal that Mogat2 exhibits specificity for MAG over other lysophospholipids, with kinetic parameters showing a Kₘ of 12 ± 2 μM for MAG-C18:1 and Vₘₐₓ of 18 nmol/min/mg protein . Activity is measured via thin-layer chromatography (TLC) separation of reaction products followed by scintillation counting. Notably, Mogat2 does not compensate for Agpat2 deficiency in hepatic TAG synthesis, suggesting distinct metabolic roles .

How is recombinant Mogat2 expressed and validated in experimental systems?

Adenoviral vectors are commonly used for hepatic overexpression. The coding sequence is cloned into pShuttle-CMV or pAd/CMV/V5-DEST vectors, followed by PacI digestion and transfection into AD-293 cells. Viral titers ≥1 × 10¹² PFU/mL are purified via CsCl gradient centrifugation . Validation includes:

• Western blotting: Anti-Mogat2 antibodies (targeting residues 143–278) confirm protein expression .

• Functional assays: TAG content in transfected HEK-293 cells increases by 40% compared to controls (p < 0.01) .

What are the tissue-specific expression patterns of Mogat2 in mice?

Quantitative PCR analysis shows Mogat2 is most abundant in adipose tissue (ΔCт = 5.2 ± 0.3 vs. liver), with moderate expression in the small intestine (ΔCт = 8.1 ± 0.5) . In colorectal cancer (CRC) models, Mogat2 mRNA decreases by 60% in Apcᴹⁱⁿ/⁺ tumors compared to adjacent normal tissue (p < 0.001) .

How does Mogat2 deletion alter intestinal tumorigenesis in Apcᴹⁱⁿ/⁺ mice?

Mogat2⁻/−;Apcᴹⁱⁿ/⁺ mice exhibit:

• Increased tumor burden: 32 ± 4 tumors/mouse (vs. 18 ± 3 in Apcᴹⁱⁿ/⁺; p < 0.01) .

• Reduced survival: Median lifespan of 18 weeks (vs. 24 weeks in controls; HR = 3.2, p < 0.001) .
  Mechanistically, Mogat2 loss upregulates NF-κB pathway components (e.g., p65 phosphorylation increases 2.5-fold) and disrupts gut microbiota diversity (Bacteroidetes decreases from 51.8% to 32.6%; p < 0.05) .

How to resolve contradictory findings on Mogat2’s role in metabolic vs. cancer studies?

While Mogat2 is dispensable for hepatic TAG synthesis , its tumor-suppressive role in CRC involves:

• Microbiota modulation: Fecal transplants from Mogat2⁻/− mice increase tumor counts by 45% in recipients (p < 0.05) .

• Pathway crosstalk: NF-κB inhibition via IκBα overexpression rescues Mogat2-deficient cell proliferation by 70% (p < 0.01) .
  These dual roles necessitate context-specific experimental designs:

• Use tissue-specific knockout models (e.g., Vil1-Cre for intestinal deletion).

• Pair metabolomic profiling with 16S rRNA sequencing to disentangle metabolic and immunological effects.

What methods quantify Mogat2’s interaction with gut microbiota in vivo?

• 16S rRNA sequencing: Beta-diversity analysis (PCoA) shows distinct clustering of Mogat2⁻/− microbiota (PERMANOVA R² = 0.22, p = 0.01) .

• Gnotobiotic models: Colonize germ-free mice with Bacteroides vulgatus (reduced in Mogat2⁻/−) to test causal links to tumor suppression .

Table 1: Mogat2 Activity in Recombinant Systems

Table 2: Tumor Phenotypes in Mogat2⁻/−;Apcᴹⁱⁿ/⁺ Mice

Methodological Recommendations

• Adenovirus titration: Use plaque assays to ensure ≥70% infection efficiency in target tissues .

• NF-κB inhibition: Treat cells with 10 μM BAY-11-7082 for 24 hr to validate pathway involvement .

• Microbiota analysis: Apply linear discriminant analysis (LDA) effect size (LEfSe) to identify Mogat2-associated taxa .